Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by ValuEngine

ValuEngine lowered shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning, ValuEngine reports.

Several other equities research analysts have also commented on TEVA. UBS Group set a $8.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Friday, August 16th. Gabelli upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a report on Wednesday, October 16th. Raymond James reduced their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an outperform rating for the company in a research note on Thursday, August 8th. SunTrust Banks decreased their price objective on shares of Teva Pharmaceutical Industries to $7.00 and set a hold rating on the stock in a report on Thursday, August 8th. Finally, Royal Bank of Canada restated a hold rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 8th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $10.64.

TEVA opened at $10.26 on Tuesday. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The business has a 50 day simple moving average of $9.03 and a 200-day simple moving average of $8.37. The stock has a market capitalization of $11.20 billion, a P/E ratio of 3.66, a P/E/G ratio of 1.12 and a beta of 1.82. Teva Pharmaceutical Industries has a 12 month low of $6.07 and a 12 month high of $21.57.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). The business had revenue of $4.26 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. Research analysts anticipate that Teva Pharmaceutical Industries will post 2.26 EPS for the current year.

In related news, VP Hafrun Fridriksdottir sold 4,310 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total value of $45,211.90. Following the sale, the vice president now owns 24,883 shares of the company’s stock, valued at approximately $261,022.67. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 18,033 shares of company stock valued at $102,261. Corporate insiders own 0.49% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Point View Wealth Management Inc. boosted its position in Teva Pharmaceutical Industries by 1.7% during the second quarter. Point View Wealth Management Inc. now owns 74,798 shares of the company’s stock worth $690,000 after acquiring an additional 1,273 shares during the last quarter. CAPROCK Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 6.2% during the third quarter. CAPROCK Group Inc. now owns 23,730 shares of the company’s stock worth $163,000 after purchasing an additional 1,378 shares during the last quarter. AdvisorNet Financial Inc boosted its holdings in shares of Teva Pharmaceutical Industries by 71.3% during the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares during the last quarter. AGF Investments America Inc. grew its position in shares of Teva Pharmaceutical Industries by 1.9% in the second quarter. AGF Investments America Inc. now owns 91,897 shares of the company’s stock valued at $848,000 after purchasing an additional 1,672 shares during the period. Finally, WealthTrust Axiom LLC increased its stake in Teva Pharmaceutical Industries by 15.0% in the second quarter. WealthTrust Axiom LLC now owns 13,049 shares of the company’s stock valued at $120,000 after purchasing an additional 1,700 shares during the last quarter. Hedge funds and other institutional investors own 54.10% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Mutual Funds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.